Pharmaceutical Market: India A Comprehensive Industry Analysis
Pharmaceutical Market: India A Comprehensive Industry Analysis
Product Code:
04052013PMI
Publication Date:
May 2013
Publisher:
Kelly Scientific Publications
Pages:
161
  • Executive Summary
  • Table of Contents
  • List of Tables
  • List of Figures
  • Companies covered

1.0 Summary

"Pharmaceutical Market: India, A Competitive Industry Analysis" by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. 

The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.

This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

1.1 Objectives of Report

The main objectives of this report are:

• To comprehensively summarize current developments in the Indian biopharmaceutical industry.
• To identify emerging trends in key markets and sub-markets such as biogenerics, cardiology, oncology therapeutics, diabetic care, vaccines and anti-infective agents.
• To comprehensive review and analyse financial and product details of key players in the industry
• To present market figures of the current Indian biopharmaceutical market value and give forecast projections and growth rates
• To identify key drivers and restraints of the Indian biopharmaceutical market
• To report and analyse market opportunities and challenges
• To identify funding and government sponsorship issues

The reader of this report will gain:

• An in-depth understanding of the Indian biopharmaceutical market and it’s environment
• Current market facts, figures and product lines of key players in the industry
• An insight into how generic therapeutics will propagate the Indian biopharmaceutical market
• Knowledge of how the Indian biopharma market will integrate into the global healthcare market
• Information on key government policies
• Data on levels of private and publically funded biopharma studies in India
• Strategies on how to adapt and restructure current business models to this industry

1.2 Scope of Study

The Indian pharmaceutical market is the main driver of the country’s healthcare industry The Indian Pharmaceutical Industry (IPI) is divided into four main sectors:
• Active Pharmaceutical Ingredients (APIs)
• Contract Research and Manufacturing Services (CRAMS)
• Formulations
• Biosimilars

The study provides a comprehensive description of current companies with an interest in the Indian market and their financial and product portfolios. This paper also identifies key therapeutics that are driving the biopharma market in India and current restraints and challenges that may weaken this emerging industry.

1.3 Data Sources and Methodology

The project leader and author of this research obtained a Ph.D. in Medicine from the Royal College of Surgeons in Ireland, following completion of a M.Sc. in Biotechnology (NUIG) and an honours degree in Biochemistry from Trinity College Dublin. She has extensive experience in drug target discovery and vaccine research and development and conducted post-doctoral studies and lecturing in Trinity College Dublin. The author’s career spans both industry and academia where she has worked with both start up biotech and multinational pharmaceutical companies. With many years of medical writing and publishing the author also has extensive experience and knowledge of genetics, molecular biology, immunology, bioinformatics and diagnostic testing. As a pharma/biotech industry analyst she has significant expertise in laboratory diagnostic testing and instrument and reagent development technology.

Sources of information for this report were collected and compiled from company specific corporate websites, annual reports, press-releases, international scientific and medical journals and news and research reports. Graphical and numerical data have been referenced and sourced accordingly. Specific websites were consulted and referenced throughout the completion of this report including that of the World Health Organization (www.who.int) and European Medicines Agency (www.ema.europa.eu).  Financial and business environment sources such as the World Trade Organization (www.WTO.org) and the International Monetary Fund (www.IMF.org) and other government agencies worldwide were also accessed. Kelly Scientific Publications has used the most recent statistical and numerical data available.  The most reliable of data sources were used in the production of this report, however we cannot guarantee complete accuracy or completeness from secondary information sources.

1.4 Key Findings and Observations

In 2012 the Indian pharmaceutical market was worth $13 billion and is forecast to become the eight largest pharma market globally by 2015. It is a significant player in emerging markets. This growth fuelled by the significant level of chronic disease in the country which is estimated at 20% of the population. Over 50% of deaths are due to chronic diseases such as cancer, cardiovascular disease and diabetes in India. Therefore a market shift from acute therapeutics to chronic medications will occur in the coming years. Vaccine production and generic drug manufacturing are key products for the Indian market and Kelly Scientific Publications predict that international markets will be significantly penetrated with these products in the near future.

The government in India has identified biotechnology as a key area of growth and to that end has provided significant funding for opportunities within this area. India’s Twelfth Five Year Plan (12th 5YP) will function to increase private investment in R&D and international collaborations. The overall aim is to position India as one of the top five scientific superpowers by 2020.

The Indian pharma market is fragmented and up to 40% of it is dominated by a small number of players including Cipla, GSK, Sun Pharma, Ranbaxy and Piramal. The IPM is divided into four key areas - active pharmaceutical ingredients (APIs), contract research and manufacturing services (CRAMS), formulations and biosimilars. The market is currently controlled by acute therapy which demanded 73% of total in 2012. This is forecast to decrease over the coming years as lifestyle and chronic disease increase further in prevalence.

1.5 Executive Summary

Today, India is the second largest country and is populated by more than 1.2 billion. By 2050, it is estimated that the population will have grown to between 1.6-1.8 billion and so key investments and strategies to exploit this growing market is paramount. India’s potential as a key player in the pharma market is significant.

The population of India over 60 years old is forecast to reach 300 million by 2050. This is a 17% increase from 77 million in 2001. Noncommunicable diseases (NCDs) such as heart disease, stroke, cancer, chronic respiratory disease, diabetes, mental health issues, vision and hearing difficulties will all increase in incidence with this population growth and put pressure on health services. According to the World Health Organisation (WHO), 80% of adult deaths are due to NCDs in urban centres and 60% of deaths in rural areas.

Over 20% of the Indian population are currently suffering from a chronic disease and 10% have comorbidities. Chronic diseases cause 50% of all deaths in India. Infectious and parasitic diseases are a significant contributor, as are cardiovascular diseases, respiratory conditions, cancer and diabetes. According to a study by Patel et al in The Lancet, almost 75% of all deaths in India will be due to a chronic disease in 2030.
• Cancer fatalities will rise from 730,000 in 2004 to 1.5 million in 2030.
• Cardiovascular deaths will increase from 2.7 million in 2004 to 4 million in 2030.
• Coronary heart disease deaths will increase from 7.1 million in 2004 to 17.9 million in 2030.

Today, the top causes of mortality in India are:

• Cardiovascular diseases
• Cancers
• Chronic Respiratory Disease
• Respiratory infections
• Perinatal Conditions
• Diarrhoeal diseases
• Digestive diseases
• HIV/AIDS
• Tuberculosis

India’s Twelfth Five Year Plan (12th 5YP) aims to increase funding for six areas of scientific research and development until 2017. An investment of INR 1,204 billion (US $24 billion) will increase Indian R&D and boost its credibility internationally. The plan also proposes to increase the output of scientific papers from 3% globally in 2012 to 5% in 2017. Biotechnology will receive significant funding and the following areas will expand over the coming years:

• Molecular and cell biology
• Structural biology
• Immunology
• Neurobiology
• Bioengineering
• Clinical and translational research
• Regulatory sciences
• Intellectual Property (IP) technology transfer
• Nanotechnology
• Nanotechnology

The Indian Pharmaceutical market (IPM) is one of the most important emerging pharma markets and in 2012 was worth $13 billion. It is forecast to increase dramatically to $74 billion by 2020 and increase its dominance as a leading player in Asia.

The IPM is a significant driver of the domestic healthcare industry and is divided into four main sections:
• Active Pharmaceutical Ingredients (APIs)
• Contract Research and Manufacturing Services (CRAMS)
• Formulations
• Biosimilars

Almost $30 billion of Indian pharmaceutical products were exported during 2011-2012 and this is expected to hit $50 billion by 2015. The majority of exports are bulk drugs (including APIs) which contribute over 50% share. Currently, Indian bulk drug exports demand 9% of the global bulk drug market. India mainly exports to the US, which received 27% of exported APIs in 2012. This was followed by the EU (19%) and Africa (17%).

The Indian formulations market exported $8 billion during 2011-2012 and is set to reach $14 billion by 2015. The domestic formulation market consumes 80% of product manufactured and was worth
Almost $11 billion in 2012. This will rise to $16 billion by 2015.

Currently the Indian biosimilar market share is low at 3% of the global market ($1 billion). However between 2013-2015 it is forecast to grow strongly and demand 20-25% of the global biosimilar market. By 2015, the global biosimilar market is expected to reach $10 billion.

The Indian Contract Research and Manufacturing Service (CRAMS) industry is currently worth $7.6 billion. It is divided into manufacturing and research, with manufacturing services accounting for just over 60% of Indian business.  Between 2010 and 2012, the Indian CRAMS industry grew by 41% due to a large increase in outsourcing. This growth rate is triple the global average of growth rate of 12.6%. By 2015, it is forecast that the CRAMS industry in India will hit $7.8-8 billion, fuelled by the impending patent cliff and high requirement for generic manufacturing, biologics, and drug delivery technologies.


The Indian pharma market is fragmented and up to 40% of it is dominated by a small number of players including:
• Cipla
• GSK
• Sun Pharma
• Ranbaxy
• Piramal
• Zydus Cadila
• Mankind
• Lupin

Over the next number of years, it is expected that the IPM will continue to grow to as much as $74 billion by 2020 with a CAGR of between 14-16%.  Therefore by 2020, the IPM will be comparable to other developed pharma markets (excluding the US and Japan) and also to the Chinese pharma market. Significant economic indicators that will propel the IPM in the near future include:

• India is one of the fastest growing economies globally with a 16% growth increase in its pharmaceutical market 2012
• India’s sovereign credit rating rose by 2.98% during the period 2007-12
• Cumulative exports recorded during 2011-12 were $242 billion - a growth of 23%
• Imports in 2011-12 at $391 billion – a growth of 29%

The Indian pharma market is currently dominated by the acute therapy market which demanded 73% of total in 2012. This is forecast to decrease over the coming years as lifestyle and chronic disease increase further in prevalence. In 2012, the anti-infectives market held the premier position within the IPM, with 16.1% share. The following therapeutic areas all hold significant market share within the IPM:
• Anti-infectives
• Cardiac
• Gastro Intestinal
• Respiratory
• Pain/Analgesics
• Vitamins/Minerals/Nutrients
• Anti-Diabetic
• Neuro/CNS
• Dermatology
• Gynaecology

Kelly Scientific Publications believes that chronic markets such as cardiovascular, diabetes and neurology/psychiatry will all contribute to market penetration within the next five years and will maintain a fast growth rate. A shift towards disease management and prevention will steadily cause a shift in the Indian pharma market from acute to chronic areas.

India’s Twelfth Five Year Plan (12th 5YP) aims to increase funding for six areas of scientific research and development until 2017. The Indian Government has proposed an investment of INR 1,204 billion (US $24 billion) to strategically increase the number of PhD graduates, researchers and essentially boost international recognition for Indian R&D.

The12th 5YP also proposes to increase the output of scientific papers from 3% globally in 2012 to 5% in 2017. The overall aim is to position India as one of the top five scientific superpowers by 2020. In order to do this information gathered from R&D must be commercialized and current pharma/biotech companies situated in India must increase their interests in R&D. By 2017, it is envisaged that the ratio of private : public share of investments is 50:50.

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. The following companies were chosen for analysis as they have specific advantages that we believe will drive the pharmaceutical industry in India.
 
• Aurobindo Pharma
• Bharat Serums and Vaccines Ltd
• Biocon Biopharmaceuticals
• Cipla
• Divis Laboratories
• Dr Reddy’s Laboratories
• Lupin
• Mankind Pharma
• Panacea Biotech
• Piramal Group
• Ranbaxy Laboratories
• Reliance Life Sciences
• Serum Institute of India
• Sun Pharmaceuticals
• Zydus Cadila

Table Of Content

1.0 Summary
1.1 Objectives of Report
1.2 Scope of Study
1.3 Data Sources and Methodology
1.4 Key Findings and Observations
1.5 Executive Summary
2.0 Epidemiology and Disease Overview
2.1 Cardiovascular Disease
2.2 Infectious Disease
2.3 Respiratory Infections
2.4 Tuberculosis
2.5 HIV
2.6 Hepatitis
2.7 Typhoid Fever
2.8 Dengue Fever
2.9 Diabetes
2.10 Cancer
2.11 Chronic Respiratory Disease- Asthma and COPD
3.0 Twelfth Five Year Plan – A Boost for Scientific Research and Development
4.0 Economic and Business Environment
4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
4.2 Gross Domestic Product of India, Historic and Projection Analysis
4.3 Global and India Economic Outlook 2010-2013
4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe)
5.0 Indian Pharmaceutical Industry
5.1 Overview
5.2 Formulations Market
5.3 Active Pharmaceutical Ingredient Market
5.4 Biosimilar Market
5.5 Contract Research and Manufacturing Service (CRAMS)
5.6 Indian Pharmaceutical Industry Market
5.7 Evaluation of Market Share by Therapeutic Area
5.8 Key Players
6.0 Indian Pharmaceutical Company Profiles and Financial Data
6.1 Aurobindo Pharma
6.2 Bharat Serums and Vaccines Ltd
6.3 Biocon Biopharmaceuticals
6.4 Cipla
6.5 Divis Laboratories
6.6 Dr Reddy’s Laboratories
6.7 Lupin
6.8 Mankind Pharma
6.9 Panacea Biotech
6.10 Piramal Group
6.11 Ranbaxy Laboratories
6.12 Reliance Life Sciences
6.13 Serum Institute of India
6.14 Sun Pharmaceuticals
6.15 Zydus Cadila
7.0 SWOT Analysis of Indian Pharmaceutical Market
7.1 Growth Factors
7.2 Strengths of Indian Pharmaceutical Industry
7.3 Main Weaknesses
7.4 Significant Opportunities within the Indian Pharmaceutical Industry
7.5 Threats and Considerations
8.0 Company Directory and Key People
8.1 Aurobindo Pharma
8.2 Bharat Serums and Vaccines Ltd
8.3 Biocon Biopharmaceuticals
8.4 Cipla
8.5 Divis laboratories
8.6 Dr Reddy’s Laboratories
8.7 Lupin
8.8 Panacea Biotech
8.9 Reliance Life Sciences
9.0 Appendix
9.1 Comprehensive List of Pharmaceutical Company’s in India

List Of Tables

Exhibit 2.1: Key Statistics: India
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030
Exhibit 2.7: Cardiovascular Mortality by Indian State
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children, (aged less than five)
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011
Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011
Exhibit 2.18: TB Vaccine Development Pipeline 2012
Exhibit 2.19: HIV Prevalence in India 2004-2009
Exhibit 2.20:  Routes of HIV Transmission in India 2011
Exhibit 2.21: Global Hepatitis E Virus Endemicity
Exhibit 2.22: Prevalence of Diabetes by Indian Region
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011
Exhibit 2.24:  Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female
Exhibit 2.26:  Incidence and Mortality Rates for Top Sixteen Cancers in India -  Men
Exhibit 2.27:  Incidence and Mortality Rates for Top Sixteen Cancers in India - Women
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes
Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes
Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer’s in India
Exhibit 2.30: Mortality Rate (per 100,000) Attributable to Chronic Obstructive Pulmonary Disease Globally
Exhibit 3.1: India’s Twelve Year Plan – Key Points in Relation to Science Research and Development
Exhibit 3.2: Budget for Specific Scientific Departments under India’s Twelfth Five Year Plan
Exhibit 4.1: World Trade Organisation Basic Indicators on India
Exhibit 4.2: World Trade Organisation Merchandise Trade Statistics: India
Exhibit 4.3: World Trade Organisation Commercial Services Trade Statistics: India
Exhibit 4.4: World Trade Organisation Industrial Property Statistics: India
Exhibit 4.5: India GDP Exhibits 2011-2018
Exhibit 4.6: India Health Expenditure as a Percentage of GDP 2000-2010
Exhibit 4.7: Global and Emerging Market and Developing Countries Economic Growth Change 2010-2013
Exhibit 4.8: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
Exhibit 4.9: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013
Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013
Exhibit 4.11: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
Exhibit 4.12: Global, US and Germany Economic Growth 2010-2013
Exhibit 4.13: US and UK Gross Domestic Product per capita Forecast 2010-2017
Exhibit 4.14: Global, France and Italy Economic Growth 2010-2013
Exhibit 4.15: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017
Exhibit 4.16: Global, UK and Spain Economic Growth 2010-2013
Exhibit 4.17: Global, Japan and Canada Economic Growth 2010-2013
Exhibit 4.18: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry
Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015
Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015
Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015
Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015
Exhibit 5.6: Geographic Distribution of India’s Active Pharmaceutical Ingredient Exports, 2012
Exhibit 5.7: Current Trends of the Global Biosimilar Market
Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market
Exhibit 5.9: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry
Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry
Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015
Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market
Exhibit 5.13: India - Significant Economic Indicators
Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market
Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012
Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011
Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market
Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area
Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012
Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market
Exhibit 5.21: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue
Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market
Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio
Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio
Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio
Exhibit 6.12: Aurobindo Pharma Alzheimer’s Product Portfolio
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio
Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012
Exhibit 6.22: Aurobindo Pharma Subsidiary Companies
Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies
Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones
Exhibit 6.25: Bharat Serums and Vaccines Range of Products
Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio
Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio
Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio
Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio
Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio
Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio
Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio
Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio
Exhibit 6.34: Biocon Biophamaceuticals Business Outline
Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas
Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies
Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones
Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas
Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas
Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations
Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics
Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics
Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics
Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics
Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics
Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics
Exhibit 6.47: Biocon Biopharmaceuticals – Syngene Service Platform
Exhibit 6.48: Biocon Biopharmaceuticals – Clinigene Service Platform
Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012
Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012
Exhibit 6.53: Cipla Important Milestones
Exhibit 6.54: Cipla Main Therapeutics Areas of Interest
Exhibit 6.55: Cipla Export Market Share FY2011-2012
Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012
Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012
Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012
Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012
Exhibit 6.60: Divis Laboratories Important Milestones
Exhibit 6.61: Divis Laboratories Product Category Portfolio
Exhibit 6.62: Divis Laboratories Product List
Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012
Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio
Exhibit 6.65: Dr Reddy’s Therapeutic Areas of Interest
Exhibit 6.66: Dr Reddy’s Laboratories – Important Milestones
Exhibit 6.67: Dr Reddy’s Labs Top Active Pharmaceutical Ingredients
Exhibit 6.68: Dr Reddy’s Labs Top Brands in India
Exhibit 6.69: Dr Reddy’s Laboratories Annual Revenue Exhibits 2003-2012
Exhibit 6.70: Dr Reddy’s Laboratories Historical Revenue Exhibits 2003-2012 (Global)
Exhibit 6.71: Dr Reddy’s Laboratories Geographical Revenue Percentage 2012
Exhibit 6.72: Dr Reddy’s Key Brand Revenue in Russia 2011-2012
Exhibit 6.73: Dr Reddy’s Key Brand Revenue in India 2011-2012
Exhibit 6.74: Dr Reddy’s Therapeutic Agents and Classes undergoing Clinical Trials
Exhibit 6.75: Lupin Significant Milestones
Exhibit 6.76: Lupin Ltd Formulations Product Portfolio
Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio
Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution
Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012
Exhibit 6.80: Lupin Ltd  Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012
Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012
Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012
Exhibit 6.83: Lupin Ltd Profit Before Tax 2008-2012
Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking
Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth
Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market
Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market
Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market
Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market
Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market
Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market
Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market
Exhibit 6.92: Lupin Ikonic Key Products and Rank in the Indian Market
Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012
Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market
Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market
Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012
Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area
Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio
Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise
Exhibit 6.100: Mankind Pharma Company Divisions
Exhibit 6.101:: Mankind Pharma Key Milestones
Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest
Exhibit 6.103: Mankind Pharma Prescription Product Areas
Exhibit 6.104: Mankind Pharma Top Ten Brands
Exhibit 6.105: Mankind Pharma Diabetic Product Brands
Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands
Exhibit 6.107: Mankind Pharma Cough  Product Brands
Exhibit 6.108: Mankind Pharma Malaria Product Brands
Exhibit 6.109: Mankind Pharma Migraine Product Brands
Exhibit 6.110: Mankind Pharma Anti-viral Product Brands
Exhibit 6.111: Mankind Pharma Steroid Product Brands
Exhibit 6.112: Mankind Pharma Dermatology Product Brands
Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands
Exhibit 6.114: Mankind Pharma Gynaecology Product Brands
Exhibit 6.115: Mankind Pharma Antibiotic Product Brands
Exhibit 6.116: Mankind Pharma Asthmatic Product Brands
Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure
Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest
Exhibit 6.119: Panacea Biotech Leading Brands in India
Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio
Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range
Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range
Exhibit 6.123: Panacea Biotech Vaccine Portfolio
Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio
Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio
Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio
Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio
Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio
Exhibit 6.129: Panacea Biotech Constipation Product Portfolio
Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio
Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio
Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care
Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management
Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment
Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment
Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal
Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Penicillins
Exhibit 6.138: Panacea Biotech Current Patents for Licencing
Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012
Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012
Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012
Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012
Exhibit 6.143: Key Milestones in Piramal Group History
Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012
Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales (Percentage) 2012
Exhibit 6.146: Piramal Pharma Solutions Sales (Rs Crores) from Domestic and International Assets 2011-2012
Exhibit 6.147: Piramal Oncology Therapeutic Pipeline
Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline
Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline
Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline
Exhibit 6.151: Ranbaxy Laboratories – Therapeutic Markets of Interest
Exhibit 6.152: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System
Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics
Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006
Exhibit 6.155: List of Ranbaxy Subsidiary Companies 
Exhibit 6.156: Ranbaxy – Future Therapeutic Areas
Exhibit 6.157: Ranbaxy Global Sales by Geographical Region
Exhibit 6.158: Ranbaxy Global Sale Exhibits by Geographical Region
Exhibit 6.159: Ranbaxy Geographical Market Share Percentage
Exhibit 6.160: Ranbaxy Developed and Emerging Market Share
Exhibit 6.161: Ranbaxy Sales Exhibits, USA and Canada
Exhibit 6.162: Ranbaxy Sales Exhibits, Europe
Exhibit 6.163: Ranbaxy Top Sellers in India
Exhibit 6.164: Ranbaxy Sales Figures, India
Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India
Exhibit 6.166: Ranbaxy Launches by Geographical Region
Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas
Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas
Exhibit 6.169: Reliance Life Sciences Clinical Research Services
Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas
Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas
Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio
Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio
Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio
Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio
Exhibit 6.176: Reliance Life Science R&D Activities
Exhibit 6.177: Serum Institute of India Significant Milestones 
Exhibit 6.178: Serum Institute of India Manufactured Products
Exhibit 6.179: Serum Institute of India Exported Products
Exhibit 6.180: Serum Institute of India Product Pipeline
Exhibit 6.181: Sun Pharmaceuticals – Important Milestones
Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage)
Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions)
Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012
Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India
Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area
Exhibit 6.187: Zydus Research Centre Speciality Areas of Research
Exhibit 6.188: Zydus Cadila Vaccine R&D Areas of Research
Exhibit 6.189: Zydus Cadila Global ‘Beyond the Billion’ Business Development Strategy
Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market
Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline
Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline
Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012
Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012
Exhibit 6.195: Zydus Cadila List of Subsidiary Companies
Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012
Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest
Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market
Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020
Exhibit 7.3: Strengths of the Indian Pharmaceutical Market
Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market
Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market
Exhibit 7.6: Threats to the Indian Pharmaceutical Market
Exhibit 8.1: Aurobindo Pharma Key Contact Details
Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel
Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details
Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors
Exhibit 8.5: Biocon Biopharmaceuticals  Key Contact Details
Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors
Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team
Exhibit 8.8: Cipla Executive Directors
Exhibit 8.9: Cipla Non-Executive/Independent Directors
Exhibit 8.10: Cipla Corporate Contact Details
Exhibit 8.11: Divis Laboratories Key Contact Details
Exhibit 8.12: Divis Laboratories Key People
Exhibit 8.13: Dr Reddy’s Laboratories Contact Information
Exhibit 8.14: Dr Reddy’s Laboratories Key People
Exhibit 8.15: Dr Reddy’s Laboratories Board of Directors
Exhibit 8.16: Dr Reddy’s Audit Committee Members
Exhibit 8.17: Dr Reddy’s Nomination, Governance & Compensation Committee Members
Exhibit 8.18: Dr Reddy’s Risk Management Committee Members
Exhibit 8.19: Dr Reddy’s Science, Technology and Operations Committee Members
Exhibit 8.20: Dr Reddy’s Shareholders’ Grievance Committee Members
Exhibit 8.21: Dr Reddy’s Investment Committee Members
Exhibit 8.22: Dr Reddy’s Management Committee Members
Exhibit 8.23: Lupin Board of  Directors
Exhibit 8.24: Lupin Key Management Players
Exhibit 8.25: Lupin Ltd General Contact Details
Exhibit 8.26: Panacea Biotech – Whole Time Directors
Exhibit 8.27: Panacea Biotech – Independent Directors
Exhibit 8.28: Panacea Biotech – Investor Contact Details
Exhibit 8.29: Panacea Biotech – General Contact Details
Exhibit 8.30: Reliance Life Sciences – General Contact Details

List Of Figures

Exhibit 2.1: Key Statistics: India
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030
Exhibit 2.7: Cardiovascular Mortality by Indian State
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children, (aged less than five)
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011
Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011
Exhibit 2.18: TB Vaccine Development Pipeline 2012
Exhibit 2.19: HIV Prevalence in India 2004-2009
Exhibit 2.20:  Routes of HIV Transmission in India 2011
Exhibit 2.21: Global Hepatitis E Virus Endemicity
Exhibit 2.22: Prevalence of Diabetes by Indian Region
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011
Exhibit 2.24:  Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female
Exhibit 2.26:  Incidence and Mortality Rates for Top Sixteen Cancers in India -  Men
Exhibit 2.27:  Incidence and Mortality Rates for Top Sixteen Cancers in India - Women
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes
Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes
Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer’s in India
Exhibit 2.30: Mortality Rate (per 100,000) Attributable to Chronic Obstructive Pulmonary Disease Globally
Exhibit 3.1: India’s Twelve Year Plan – Key Points in Relation to Science Research and Development
Exhibit 3.2: Budget for Specific Scientific Departments under India’s Twelfth Five Year Plan
Exhibit 4.1: World Trade Organisation Basic Indicators on India
Exhibit 4.2: World Trade Organisation Merchandise Trade Statistics: India
Exhibit 4.3: World Trade Organisation Commercial Services Trade Statistics: India
Exhibit 4.4: World Trade Organisation Industrial Property Statistics: India
Exhibit 4.5: India GDP Exhibits 2011-2018
Exhibit 4.6: India Health Expenditure as a Percentage of GDP 2000-2010
Exhibit 4.7: Global and Emerging Market and Developing Countries Economic Growth Change 2010-2013
Exhibit 4.8: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
Exhibit 4.9: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013
Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013
Exhibit 4.11: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
Exhibit 4.12: Global, US and Germany Economic Growth 2010-2013
Exhibit 4.13: US and UK Gross Domestic Product per capita Forecast 2010-2017
Exhibit 4.14: Global, France and Italy Economic Growth 2010-2013
Exhibit 4.15: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017
Exhibit 4.16: Global, UK and Spain Economic Growth 2010-2013
Exhibit 4.17: Global, Japan and Canada Economic Growth 2010-2013
Exhibit 4.18: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry
Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015
Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015
Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015
Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015
Exhibit 5.6: Geographic Distribution of India’s Active Pharmaceutical Ingredient Exports, 2012
Exhibit 5.7: Current Trends of the Global Biosimilar Market
Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market
Exhibit 5.9: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry
Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry
Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015
Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market
Exhibit 5.13: India - Significant Economic Indicators
Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market
Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012
Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011
Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market
Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area
Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012
Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market
Exhibit 5.21: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue
Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market
Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio
Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio
Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio
Exhibit 6.12: Aurobindo Pharma Alzheimer’s Product Portfolio
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio
Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012
Exhibit 6.22: Aurobindo Pharma Subsidiary Companies
Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies
Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones
Exhibit 6.25: Bharat Serums and Vaccines Range of Products
Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio
Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio
Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio
Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio
Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio
Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio
Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio
Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio
Exhibit 6.34: Biocon Biophamaceuticals Business Outline
Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas
Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies
Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones
Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas
Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas
Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations
Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics
Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics
Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics
Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics
Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics
Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics
Exhibit 6.47: Biocon Biopharmaceuticals – Syngene Service Platform
Exhibit 6.48: Biocon Biopharmaceuticals – Clinigene Service Platform
Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012
Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012
Exhibit 6.53: Cipla Important Milestones
Exhibit 6.54: Cipla Main Therapeutics Areas of Interest
Exhibit 6.55: Cipla Export Market Share FY2011-2012
Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012
Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012
Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012
Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012
Exhibit 6.60: Divis Laboratories Important Milestones
Exhibit 6.61: Divis Laboratories Product Category Portfolio
Exhibit 6.62: Divis Laboratories Product List
Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012
Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio
Exhibit 6.65: Dr Reddy’s Therapeutic Areas of Interest
Exhibit 6.66: Dr Reddy’s Laboratories – Important Milestones
Exhibit 6.67: Dr Reddy’s Labs Top Active Pharmaceutical Ingredients
Exhibit 6.68: Dr Reddy’s Labs Top Brands in India
Exhibit 6.69: Dr Reddy’s Laboratories Annual Revenue Exhibits 2003-2012
Exhibit 6.70: Dr Reddy’s Laboratories Historical Revenue Exhibits 2003-2012 (Global)
Exhibit 6.71: Dr Reddy’s Laboratories Geographical Revenue Percentage 2012
Exhibit 6.72: Dr Reddy’s Key Brand Revenue in Russia 2011-2012
Exhibit 6.73: Dr Reddy’s Key Brand Revenue in India 2011-2012
Exhibit 6.74: Dr Reddy’s Therapeutic Agents and Classes undergoing Clinical Trials
Exhibit 6.75: Lupin Significant Milestones
Exhibit 6.76: Lupin Ltd Formulations Product Portfolio
Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio
Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution
Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012
Exhibit 6.80: Lupin Ltd  Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012
Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012
Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012
Exhibit 6.83: Lupin Ltd Profit Before Tax 2008-2012
Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking
Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth
Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market
Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market
Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market
Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market
Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market
Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market
Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market
Exhibit 6.92: Lupin Ikonic Key Products and Rank in the Indian Market
Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012
Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market
Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market
Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012
Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area
Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio
Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise
Exhibit 6.100: Mankind Pharma Company Divisions
Exhibit 6.101:: Mankind Pharma Key Milestones
Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest
Exhibit 6.103: Mankind Pharma Prescription Product Areas
Exhibit 6.104: Mankind Pharma Top Ten Brands
Exhibit 6.105: Mankind Pharma Diabetic Product Brands
Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands
Exhibit 6.107: Mankind Pharma Cough  Product Brands
Exhibit 6.108: Mankind Pharma Malaria Product Brands
Exhibit 6.109: Mankind Pharma Migraine Product Brands
Exhibit 6.110: Mankind Pharma Anti-viral Product Brands
Exhibit 6.111: Mankind Pharma Steroid Product Brands
Exhibit 6.112: Mankind Pharma Dermatology Product Brands
Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands
Exhibit 6.114: Mankind Pharma Gynaecology Product Brands
Exhibit 6.115: Mankind Pharma Antibiotic Product Brands
Exhibit 6.116: Mankind Pharma Asthmatic Product Brands
Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure
Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest
Exhibit 6.119: Panacea Biotech Leading Brands in India
Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio
Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range
Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range
Exhibit 6.123: Panacea Biotech Vaccine Portfolio
Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio
Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio
Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio
Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio
Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio
Exhibit 6.129: Panacea Biotech Constipation Product Portfolio
Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio
Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio
Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care
Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management
Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment
Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment
Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal
Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Penicillins
Exhibit 6.138: Panacea Biotech Current Patents for Licencing
Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012
Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012
Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012
Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012
Exhibit 6.143: Key Milestones in Piramal Group History
Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012
Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales (Percentage) 2012
Exhibit 6.146: Piramal Pharma Solutions Sales (Rs Crores) from Domestic and International Assets 2011-2012
Exhibit 6.147: Piramal Oncology Therapeutic Pipeline
Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline
Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline
Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline
Exhibit 6.151: Ranbaxy Laboratories – Therapeutic Markets of Interest
Exhibit 6.152: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System
Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics
Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006
Exhibit 6.155: List of Ranbaxy Subsidiary Companies 
Exhibit 6.156: Ranbaxy – Future Therapeutic Areas
Exhibit 6.157: Ranbaxy Global Sales by Geographical Region
Exhibit 6.158: Ranbaxy Global Sale Exhibits by Geographical Region
Exhibit 6.159: Ranbaxy Geographical Market Share Percentage
Exhibit 6.160: Ranbaxy Developed and Emerging Market Share
Exhibit 6.161: Ranbaxy Sales Exhibits, USA and Canada
Exhibit 6.162: Ranbaxy Sales Exhibits, Europe
Exhibit 6.163: Ranbaxy Top Sellers in India
Exhibit 6.164: Ranbaxy Sales Figures, India
Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India
Exhibit 6.166: Ranbaxy Launches by Geographical Region
Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas
Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas
Exhibit 6.169: Reliance Life Sciences Clinical Research Services
Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas
Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas
Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio
Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio
Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio
Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio
Exhibit 6.176: Reliance Life Science R&D Activities
Exhibit 6.177: Serum Institute of India Significant Milestones 
Exhibit 6.178: Serum Institute of India Manufactured Products
Exhibit 6.179: Serum Institute of India Exported Products
Exhibit 6.180: Serum Institute of India Product Pipeline
Exhibit 6.181: Sun Pharmaceuticals – Important Milestones
Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage)
Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions)
Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012
Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India
Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area
Exhibit 6.187: Zydus Research Centre Speciality Areas of Research
Exhibit 6.188: Zydus Cadila Vaccine R&D Areas of Research
Exhibit 6.189: Zydus Cadila Global ‘Beyond the Billion’ Business Development Strategy
Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market
Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline
Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline
Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012
Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012
Exhibit 6.195: Zydus Cadila List of Subsidiary Companies
Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012
Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest
Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market
Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020
Exhibit 7.3: Strengths of the Indian Pharmaceutical Market
Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market
Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market
Exhibit 7.6: Threats to the Indian Pharmaceutical Market
Exhibit 8.1: Aurobindo Pharma Key Contact Details
Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel
Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details
Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors
Exhibit 8.5: Biocon Biopharmaceuticals  Key Contact Details
Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors
Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team
Exhibit 8.8: Cipla Executive Directors
Exhibit 8.9: Cipla Non-Executive/Independent Directors
Exhibit 8.10: Cipla Corporate Contact Details
Exhibit 8.11: Divis Laboratories Key Contact Details
Exhibit 8.12: Divis Laboratories Key People
Exhibit 8.13: Dr Reddy’s Laboratories Contact Information
Exhibit 8.14: Dr Reddy’s Laboratories Key People
Exhibit 8.15: Dr Reddy’s Laboratories Board of Directors
Exhibit 8.16: Dr Reddy’s Audit Committee Members
Exhibit 8.17: Dr Reddy’s Nomination, Governance & Compensation Committee Members
Exhibit 8.18: Dr Reddy’s Risk Management Committee Members
Exhibit 8.19: Dr Reddy’s Science, Technology and Operations Committee Members
Exhibit 8.20: Dr Reddy’s Shareholders’ Grievance Committee Members
Exhibit 8.21: Dr Reddy’s Investment Committee Members
Exhibit 8.22: Dr Reddy’s Management Committee Members
Exhibit 8.23: Lupin Board of  Directors
Exhibit 8.24: Lupin Key Management Players
Exhibit 8.25: Lupin Ltd General Contact Details
Exhibit 8.26: Panacea Biotech – Whole Time Directors
Exhibit 8.27: Panacea Biotech – Independent Directors
Exhibit 8.28: Panacea Biotech – Investor Contact Details
Exhibit 8.29: Panacea Biotech – General Contact Details
Exhibit 8.30: Reliance Life Sciences – General Contact Details

Companies Covered

• Aurobindo Pharma
• Bharat Serums and Vaccines Ltd
• Biocon Biopharmaceuticals
• Cipla
• Divis Laboratories
• Dr Reddy’s Laboratories
• Lupin
• Mankind Pharma
• Panacea Biotech
• Piramal Group
• Ranbaxy Laboratories
• Reliance Life Sciences
• Serum Institute of India
• Sun Pharmaceuticals
• Zydus Cadila

Related Reports
Title
Published
Price